SABS
SAB Biotherapeutics Inc
3.10$
+4.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
SAB Biotherapeutics Inc (SABS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -24 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.0 | 4.8 | 9.5 | -6.4 | 3.8 | 4.3 | -9.5 | -4.4 | -8.2 | 0.2 | -1.6 | -4.9 | -5.2 | -13 | -11 | -7.8 | -6.3 | -9.3 | -7.8 | -7.2 | -13 | -17 | -14 | -24 | -68 | |
| 0.1 | 0.2 | 0.3 | 0.3 | 0.4 | 0.0 | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 | 0.9 | 1.0 | 0.9 | 2.0 | 1.0 | 1.0 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 1.6 | 3.9 | |
| – | – | 0.3 | 0.4 | 0.9 | 0.0 | 0.9 | 0.6 | 0.6 | 0.3 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.6 | 1.0 | 0.7 | 0.6 | 0.6 | 0.2 | 3.2 | 5.5 | 13 | 22 | |
| 0.1 | 0.2 | -0.3 | 0.1 | 0.0 | 4.8 | -7.0 | -1.2 | -0.2 | 0.6 | 7.3 | 1.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | 8.1 | -4.2 | 6.6 | 13 | -4.2 | 0.7 | -1.8 | 20 | 4.2 | 0.0 | -1.5 | -0.4 | -2.8 | 0.3 | 2.1 | -1.9 | 1.1 | 0.9 | 1.6 | -7.3 | -2.1 | 1.2 | -6.6 | |
| 5.5 | 5.5 | 1.9 | 3.5 | 3.2 | 5.4 | 1.4 | 0.6 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.9 | 1.0 | 2.6 | 4.5 | |
| -5.5 | -5.4 | -1.9 | -3.5 | -3.2 | -2.4 | -1.3 | -0.6 | -0.1 | -0.1 | 0.0 | 0.0 | 0.0 | -0.1 | -31 | 11 | -1.2 | 9.3 | 4.7 | 5.2 | -130 | -1.7 | -66 | -71 | -268 | |
| – | – | 0.0 | – | – | -4.2 | -5.5 | 0.0 | 0.0 | 0.0 | -4.2 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | 0.0 | – | |
| -0.1 | -0.1 | 0.0 | 0.0 | -0.1 | -0.1 | 0.0 | 0.0 | 0.0 | -1.1 | 1.9 | -0.3 | – | – | – | – | -0.6 | 0.2 | -0.2 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | |
| 5.0 | 2.4 | 0.0 | 0.0 | -0.1 | -83 | -6.3 | -0.7 | 0.0 | 6.6 | -0.4 | -0.4 | -0.1 | 68 | -0.2 | -0.3 | -0.7 | 0.0 | -0.2 | -0.2 | 169 | 0.0 | 90 | 92 | 351 | |
| 4.5 | 1.8 | 7.5 | -9.9 | 0.5 | 39 | -17 | -5.8 | -8.3 | 6.7 | -2.0 | -5.3 | -5.3 | 54 | -43 | 3.2 | -8.1 | -0.3 | -3.3 | -1.9 | 26 | -19 | 10 | -2.2 | 15 | |
| – | – | 7.6 | -9.8 | 0.6 | 9.7 | -11 | -5.1 | -8.3 | 19 | -1.6 | -4.9 | -5.3 | -14 | -11 | -7.8 | -6.4 | -9.3 | -7.8 | -7.2 | -13 | -18 | -15 | -27 | -73 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.